Aphria (TSE:APH) had its price target increased by equities research analysts at Canaccord Genuity from C$8.25 to C$14.00 in a research report issued on Tuesday. Canaccord Genuity’s price target suggests a potential upside of 3.93% from the stock’s previous close.

Aphria (TSE APH) opened at C$13.47 on Tuesday. Aphria has a twelve month low of C$4.06 and a twelve month high of C$14.89.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/05/aphria-aph-upgraded-to-speculative-buy-by-canaccord-genuity.html.

About Aphria

Aphria Inc produces, supplies, and sells medical cannabis in Canada. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It also provides support services in the form of medical consultations, group therapies, and rehabilitation to veteran and first responders.

Receive News & Ratings for Aphria Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria Inc and related companies with MarketBeat.com's FREE daily email newsletter.